Staphefekt

Staphefekt is a proprietary enzyme (an endolysin) intended to treat Staphylococcus aureus skin infections in humans. The product is developed and produced by Dutch biotechnology company Micreos.^[1]^[2]

The enzyme has been shown to be effective in killing S. aureus strains resistant to antibiotics such as MRSA.^[3]

References

^ Parmley, Stephen (2014-12-11). "Lysin in wait". SciBX: Science-Business eXchange. 7 (47). doi:10.1038/scibx.2014.1369.
^ Herpers, Bjorn (2015-03-01). "Endolysins: redefining antibacterial therapy". Future Microbiology. 10 (3): 309–311. doi:10.2217/fmb.14.142. ISSN 1746-0913.
^ Siew, Adeline (Apr 21, 2015). "Endolysin Technology Presents an Antibiotic Alternative with Broad Applicability" – via www.pharmtech.com.

External links

Official website

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.

[1] Parmley, Stephen (2014-12-11). "Lysin in wait". SciBX: Science-Business eXchange. 7 (47). doi:10.1038/scibx.2014.1369.

[2] Herpers, Bjorn (2015-03-01). "Endolysins: redefining antibacterial therapy". Future Microbiology. 10 (3): 309–311. doi:10.2217/fmb.14.142. ISSN 1746-0913.

[3] Siew, Adeline (Apr 21, 2015). "Endolysin Technology Presents an Antibiotic Alternative with Broad Applicability" – via www.pharmtech.com.

[1]

[2]

[3]